Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Canaccord ups Price Target to $7

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Mar 02, 2021 1:43pm

100 Views

Post# 32696305

RE:RE:Canaccord ups Price Target to $7

I doubt it all the legacy analysts are full of it and full of Cheeto's they should really support the NASH protocol cause they will soon need Tesamorelin.

Wino115 wrote: I guess the upshot to that is if there is any safety and efficacy data on cancer he will have to increase it a fair amount. Then, when the Phase 3 starts he'll at least have to build a model and assign some kind of success probability to it.

The only issue here is that his firm is for sale and he/they may or may not be around or have different ownership that shuffles coverage and analysts around. I'm sort of the view now that it's been on the block so long and the markets have rallied so that if anyone were interested we'd have seen somethiing. From the newspapers it appears there's interest in their wealth management area so maybe they split in two eventually or someone buys that half.

Anyway, glad to know he's woken up from his Cheeto's coma...

SPCEO1 wrote: Ed Nash has finally published a report and he upped the price target on THTX to $7 from $6. He is doing so primarily based on a better sales outlook for the legacy drugs. So, still not much credit for NASH or cancer although both are mentioned favorably.